VCA Stocks

Osteologix Inc - About 18 months after establishing a U.S. presence in San Francisco, bone disease company Osteologix Inc. completed a reverse merger and a $10 million financing that will help move its lead product into Phase II trials. Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers.